Rett syndrome: How does Acadia’s trofinetide compare to ANAVEX2-73?
Now that Acadia’s trofinetide nabbed the first FDA approval for Rett syndrome, here’s a look at how Anavex’s Phase III candidate stacks up.
FDA guidance agenda: what is CDER cooking for clinical trials?
eConsent in clinical trials: what’s new and what’s yet to come?
Pipeline Moves: advancement prospects slump for lupus drug after negative topline data
FDA meeting highlights patient recruitment challenges on Rare Disease Day
Q&A: Ethics of ultra-rare disease drug development and expanded access
Analysis
View More
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Themes
View MoreCloudbyz launches new electronic data capture platform for clinical trials
Organisations can use the platform to optimise their research efforts and minimise manual errors.
More themes
Insights
View MoreWho’s hiring who? Hiring activity related to social responsibility increased by 10% in the pharmaceutical industry in Q3 2022
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
Clario launches comprehensive clinical trial solution
BWH’s investigators test Foralumab in pilot trial for Covid-19
Quantum medicine: how quantum computers could change drug development